386 related articles for article (PubMed ID: 22869732)
21. Mutation of the BRCA1 SQ-cluster results in aberrant mitosis, reduced homologous recombination, and a compensatory increase in non-homologous end joining.
Beckta JM; Dever SM; Gnawali N; Khalil A; Sule A; Golding SE; Rosenberg E; Narayanan A; Kehn-Hall K; Xu B; Povirk LF; Valerie K
Oncotarget; 2015 Sep; 6(29):27674-87. PubMed ID: 26320175
[TBL] [Abstract][Full Text] [Related]
22. The combination of Hsp90 inhibitor 17AAG and heavy-ion irradiation provides effective tumor control in human lung cancer cells.
Hirakawa H; Fujisawa H; Masaoka A; Noguchi M; Hirayama R; Takahashi M; Fujimori A; Okayasu R
Cancer Med; 2015 Mar; 4(3):426-36. PubMed ID: 25582113
[TBL] [Abstract][Full Text] [Related]
23. Regulation of repair pathway choice at two-ended DNA double-strand breaks.
Shibata A
Mutat Res; 2017 Oct; 803-805():51-55. PubMed ID: 28781144
[TBL] [Abstract][Full Text] [Related]
24. BRCA1 promotes unloading of the CMG helicase from a stalled DNA replication fork.
Long DT; Joukov V; Budzowska M; Walter JC
Mol Cell; 2014 Oct; 56(1):174-85. PubMed ID: 25219499
[TBL] [Abstract][Full Text] [Related]
25. Lamin-A interacting protein Hsp90 is required for DNA damage repair and chemoresistance of ovarian cancer cells.
Wang Y; Chen Q; Wu D; Chen Q; Gong G; He L; Wu X
Cell Death Dis; 2021 Aug; 12(8):786. PubMed ID: 34381017
[TBL] [Abstract][Full Text] [Related]
26. HSP90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells.
Ko JC; Chen HJ; Huang YC; Tseng SC; Weng SH; Wo TY; Huang YJ; Chiu HC; Tsai MS; Chiou RY; Lin YW
Regul Toxicol Pharmacol; 2012 Dec; 64(3):415-24. PubMed ID: 23069143
[TBL] [Abstract][Full Text] [Related]
27. BRCA1 Mutation: A Predictive Marker for Radiation Therapy?
Kan C; Zhang J
Int J Radiat Oncol Biol Phys; 2015 Oct; 93(2):281-93. PubMed ID: 26383678
[TBL] [Abstract][Full Text] [Related]
28. Analysis of chromatid-break-repair detects a homologous recombination to non-homologous end-joining switch with increasing load of DNA double-strand breaks.
Murmann-Konda T; Soni A; Stuschke M; Iliakis G
Mutat Res Genet Toxicol Environ Mutagen; 2021 Jul; 867():503372. PubMed ID: 34266628
[TBL] [Abstract][Full Text] [Related]
29. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
[TBL] [Abstract][Full Text] [Related]
30. Polo-like kinase 1 mediates BRCA1 phosphorylation and recruitment at DNA double-strand breaks.
Chabalier-Taste C; Brichese L; Racca C; Canitrot Y; Calsou P; Larminat F
Oncotarget; 2016 Jan; 7(3):2269-83. PubMed ID: 26745677
[TBL] [Abstract][Full Text] [Related]
31. The purine scaffold Hsp90 inhibitor PU-H71 sensitizes cancer cells to heavy ion radiation by inhibiting DNA repair by homologous recombination and non-homologous end joining.
Lee Y; Li HK; Masaoka A; Sunada S; Hirakawa H; Fujimori A; Nickoloff JA; Okayasu R
Radiother Oncol; 2016 Oct; 121(1):162-168. PubMed ID: 27666928
[TBL] [Abstract][Full Text] [Related]
32. FANCJ compensates for RAP80 deficiency and suppresses genomic instability induced by interstrand cross-links.
Awate S; Sommers JA; Datta A; Nayak S; Bellani MA; Yang O; Dunn CA; Nicolae CM; Moldovan GL; Seidman MM; Cantor SB; Brosh RM
Nucleic Acids Res; 2020 Sep; 48(16):9161-9180. PubMed ID: 32797166
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
Schwock J; Pham NA; Cao MP; Hedley DW
Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
[TBL] [Abstract][Full Text] [Related]
34. Loss of PTEN-assisted G2/M checkpoint impedes homologous recombination repair and enhances radio-curability and PARP inhibitor treatment response in prostate cancer.
Mansour WY; Tennstedt P; Volquardsen J; Oing C; Kluth M; Hube-Magg C; Borgmann K; Simon R; Petersen C; Dikomey E; Rothkamm K
Sci Rep; 2018 Mar; 8(1):3947. PubMed ID: 29500400
[TBL] [Abstract][Full Text] [Related]
35. Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers.
Vollebergh MA; Jonkers J; Linn SC
Cell Mol Life Sci; 2012 Jan; 69(2):223-45. PubMed ID: 21922196
[TBL] [Abstract][Full Text] [Related]
36. Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.
Ha K; Fiskus W; Choi DS; Bhaskara S; Cerchietti L; Devaraj SG; Shah B; Sharma S; Chang JC; Melnick AM; Hiebert S; Bhalla KN
Oncotarget; 2014 Jul; 5(14):5637-50. PubMed ID: 25026298
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells.
Ohba S; Hirose Y; Yoshida K; Yazaki T; Kawase T
J Neurosurg; 2010 Jan; 112(1):33-42. PubMed ID: 19408974
[TBL] [Abstract][Full Text] [Related]
38. PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells.
Noordermeer SM; van Attikum H
Trends Cell Biol; 2019 Oct; 29(10):820-834. PubMed ID: 31421928
[TBL] [Abstract][Full Text] [Related]
39. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair.
Ashworth A
J Clin Oncol; 2008 Aug; 26(22):3785-90. PubMed ID: 18591545
[TBL] [Abstract][Full Text] [Related]
40. Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells.
Gaspar N; Sharp SY; Pacey S; Jones C; Walton M; Vassal G; Eccles S; Pearson A; Workman P
Cancer Res; 2009 Mar; 69(5):1966-75. PubMed ID: 19244114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
